Saptarsi (Sap) Haldar joined Amgen as Vice President of Research in August 2018, overseeing the Cardiometabolic Disease Therapeutic Area. He also leads the Biomarkers Discovery and Research Biomics Organizations and serves as the site head for Amgen San Francisco (ASF), where approximately ~500 colleagues spanning diverse disciplines are based. He also serves as the executive sponsor for Amgen Black Employee Network’s ASF chapter. Sap joined Amgen from the Gladstone Institute of Cardiovascular Disease and University of California San Francisco, where he was a Professor of Medicine. In that role, he ran a laboratory focused on how cells in the cardiovascular and metabolic system control gene expression and how these gene control mechanisms go awry during disease. His lab had a major interest in heart failure, a very common and deadly condition that affects a large number of adults. More specifically, he has developed therapeutic approaches that target gene-control mechanisms in the stressed and failing heart, a process that has striking similarities to uncontrolled growth in cancers. Sap received his B.S. from Cornell University and M.D. from Johns Hopkins University. He trained in internal medicine at Johns Hopkins followed by Fellowship training in Cardiology at Brigham and Women’s Hospital, Harvard Medical School. He has had continuous funding from the National Institutes of Health and has been the recipient of several awards including the Jeremiah Stamler Distinguished Young Investigator Prize, appointment to the board of Associate Scientific Advisors to Science Translational Medicine, election as a Fellow of the American Heart Association, and induction into the American Society for Clinical Investigation. He has also chaired major research symposia, served on several scientific advisory boards for academic and nonprofit organizations in biomedical research, and is deeply committed to mentorship of junior colleagues, including those on a physician-scientist pathway. In addition to his lab’s research, Sap co-founded Tenaya Therapeutics, which is focused on developing therapies for heart failure. Sap is also a board-certified cardiologist who continues to actively see patients on a volunteer-basis while conducting basic research and leading cardiometabolic drug discovery